ESTEVE Acquires Rights to Caprelsa® for Treating Thyroid Cancer
Deal News | Jun 30, 2025 | PR Newswire Cision ESTEVE
ESTEVE, a global pharmaceutical company, has announced an agreement to acquire Caprelsa® (vandetanib) from Sanofi, marking a significant step in its international growth strategy. This medicine is used for treating aggressive and symptomatic medullary thyroid cancer in adults and children over the age of 5. Caprelsa® works by inhibiting protein tyrosine kinases to reduce blood supply to cancer cells, thereby slowing their growth. José María Giménez-Arnau, Chief Scientific & Medical Officer of ESTEVE, noted the importance of this acquisition in providing improved treatments for patients with this rare form of neuroendocrine tumor. This comes after ESTEVE's recent purchases of businesses and licenses that focus on rare diseases and specialized therapies. The transaction, which spans over 50 countries, is subject to regulatory approvals. ESTEVE continues to fortify its portfolio with specialized medical treatments addressing unmet medical needs, reflecting its mission to enhance global health outcomes.
Sectors
- Pharmaceuticals
- Biotechnology
Geography
- Spain – ESTEVE's headquarters is located in Barcelona, Spain, serving as the base for its international operations.
- Global – The acquisition deals with rights across more than 50 countries, highlighting the international scope of ESTEVE's operations.
Industry
- Pharmaceuticals – The acquisition of Caprelsa® and ESTEVE's focus on specialized medical treatments fall under the Pharmaceuticals industry.
- Biotechnology – The development and acquisition of treatments for rare diseases, such as medullary thyroid cancer, are significant within the Biotechnology sector.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| ESTEVE | Acquirer | Company | A global pharmaceutical company focused on specialized treatments with headquarters in Barcelona, Spain. |
| Sanofi | Vendor | Company | An international pharmaceutical company from which ESTEVE is acquiring Caprelsa®. |
| Caprelsa® (vandetanib) | Target Product | Medicine | A medicine used to treat medullary thyroid cancer, acquired by ESTEVE. |
| José María Giménez-Arnau | Chief Scientific & Medical Officer | Person | An executive at ESTEVE commenting on the acquisition's significance. |
| Jacob Tolstrup | Chief Commercial Officer | Person | An executive at ESTEVE who commented on the acquisition. |